WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2018044369) TRIPLE DRUG COMBINATION (METFORMIN, SIMVASTATIN, DIGOXIN) FOR TARGETED TREATMENT OF PANCREATIC CANCER
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.:    WO/2018/044369    International Application No.:    PCT/US2017/033512
Publication Date: 08.03.2018 International Filing Date: 19.05.2017
IPC:
A61K 9/20 (2006.01), A61K 45/06 (2006.01), A61P 3/10 (2006.01), A61P 9/00 (2006.01), A61P 9/04 (2006.01), A61P 9/10 (2006.01)
Applicants: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; 1111 Franklin Street Twelfth Floor Oakland, California 94607-5200 (US)
Inventors: BRUNICARDI, Francis C.; (US).
SANCHEZ, Robbi L.; (US)
Agent: WOOD, William J.; (US)
Priority Data:
62/338,655 19.05.2016 US
Title (EN) TRIPLE DRUG COMBINATION (METFORMIN, SIMVASTATIN, DIGOXIN) FOR TARGETED TREATMENT OF PANCREATIC CANCER
(FR) COMBINAISON DE TROIS MÉDICAMENTS (METFORMINE, SIMVASTATINE, DIGOXINE) POUR LE TRAITEMENT CIBLÉ DU CANCER DU PANCRÉAS
Abstract: front page image
(EN)A combination of three well-known and FDA approved compounds has been discovered to significantly suppress the proliferation of pancreatic cancer cells in clinically relevant models of pancreatic cancer. Embodiments of the invention include compositions of matter comprising a combination of agents such as metformin, simvastatin, and digoxin as well as methods of treating cancers using such agents. Illustrative methods include combining a population of pancreatic cancer cells with amounts of metformin, simvastatin, and digoxin sufficient to inhibit expression of BIRC5 protein in the population of pancreatic cancer cells, thereby inhibiting the growth of the population of pancreatic cancer cells.
(FR)On a découvert qu'une combinaison de trois composés bien connus et approuvés par la FDA inhibe significativement la prolifération des cellules du cancer du pancréas dans des modèles cliniquement pertinents du cancer du pancréas. Des modes de réalisation de l'invention comprennent des compositions comprenant une combinaison d'agents tels que la metformine, la simvastatine et la digoxine, ainsi que des méthodes de traitement de cancers utilisant de tels agents. Des procédés donnés à titre d'exemple comprennent la combinaison d'une population de cellules du cancer du pancréas avec des quantités de metformine, de simvastatine et de digoxine suffisantes pour inhiber l'expression de la protéine BIRC5 dans la population de cellules du cancer du pancréas, ce qui permet d'inhiber le développement de la population de cellules du cancer du pancréas.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)